Conclusions This study documents that there exists a statistically significant association between immunoexpression of RUNX2 and grade of tumor, muscle invasion, advanced stage, and lymph node metastasis in urinary bladder cancers, which can guide further management and treatment and can be utilized in the near future for the development of targeted therapy for urinary bladder cancer patients. This evidence concerns the gene RUNX2 and urinary bladder cancer.